TRAIL Antibody (N2B2): sc-56245
- TRAIL Antibody (N2B2) is a rat monoclonal IgG2a provided at 200 µg/ml
- raised against TRAIL of mouse origin
- recommended for detection of TRAIL of mouse origin by FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for TRAIL Antibody (N2B2). This work is in progress.
QUICK LINKS
SEE ALSO...
TRAIL Antibody (N2B2) is a rat monoclonal IgG2a antibody that detects TRAIL in mouse samples through flow cytometry (FCM). TRAIL, or TNF-related apoptosis-inducing ligand, plays a crucial role in regulating apoptosis, which is the process of programmed cell death essential for maintaining cellular homeostasis and immune system function. TRAIL is primarily located on the cell surface and can also be released as a soluble form, allowing TRAIL to interact with various TRAIL receptors on target cells, thereby triggering apoptotic pathways. TRAIL′s ability to induce apoptosis in cancer cells while sparing normal cells makes TRAIL a significant focus of research in cancer therapy, as TRAIL offers a potential mechanism for selectively eliminating malignant cells. TRAIL′s interaction with receptors can also influence immune responses, making TRAIL an important player in both tumor immunity and the regulation of inflammation. With unique properties and functional significance, TRAIL remains a vital component in the study of apoptosis and therapeutic strategies targeting cancer.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TRAIL Antibody (N2B2) References:
- Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. | Sayers, TJ. and Murphy, WJ. 2006. Cancer Immunol Immunother. 55: 76-84. PMID: 15864587
- The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. | Huang, Y., et al. 2005. Cell Mol Immunol. 2: 113-22. PMID: 16191417
- TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. | Cretney, E., et al. 2006. Immunol Cell Biol. 84: 87-98. PMID: 16405656
- The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. | Audo, R., et al. 2013. Cytokine. 63: 81-90. PMID: 23651570
- Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2. | Bertsch, U., et al. 2014. Cell Death Dis. 5: e1390. PMID: 25165876
- TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications. | Perri, P., et al. 2015. Biomed Res Int. 2015: 424019. PMID: 25834817
- TNF-related apoptosis-inducing ligand deficiency enhances survival in murine colon ascendens stent peritonitis. | Beyer, K., et al. 2016. J Inflamm Res. 9: 103-13. PMID: 27366100
- TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. | Naimi, A., et al. 2018. Biomed Pharmacother. 98: 566-576. PMID: 29288972
- FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma. | Tufano, M., et al. 2021. Front Cell Dev Biol. 9: 718947. PMID: 34589486
- TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study. | Tegethoff, SA., et al. 2022. Int J Infect Dis. 122: 178-187. PMID: 35643306
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRAIL Antibody (N2B2) | sc-56245 | 200 µg/ml | $322.00 | |||
TRAIL Antibody (N2B2) FITC | sc-56245 FITC | 200 µg/ml | $336.00 | |||
TRAIL Antibody (N2B2) PE | sc-56245 PE | 200 µg/ml | $349.00 |